NLS Pharmaceutics AG (NLSP)
NASDAQ: NLSP · IEX Real-Time Price · USD
0.180
-0.005 (-2.81%)
Jul 22, 2024, 11:25 AM EDT - Market open
NLS Pharmaceutics AG Employees
As of December 31, 2021, NLS Pharmaceutics AG had 7 total employees, including 6 full-time and 1 part-time employees.
Employees
7
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,738,861
Market Cap
8.08M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Syra Health | 162 |
| Zhongchao | 142 |
| Vivos Therapeutics | 123 |
| Molecular Templates | 62 |
| Organovo Holdings | 20 |
| Kineta | 13 |
| Virpax Pharmaceuticals | 7 |
| Silo Pharma | 3 |
NLSP News
- 24 days ago - NLS Pharmaceutics Announces Registered Direct Offering - Accesswire
- 25 days ago - NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments - Accesswire
- 27 days ago - Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements - Accesswire
- 5 weeks ago - NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA) - Accesswire
- 3 months ago - NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing - Accesswire
- 4 months ago - NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering - Accesswire
- 4 months ago - NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering - Accesswire
- 4 months ago - NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform - Accesswire